|
Pronunciation |
|
(sye
KLAN de
late) |
|
|
U.S. Brand
Names |
|
Cyclan®;
Cyclospasmol® |
|
|
Generic
Available |
|
Yes |
|
|
Pharmacological Index |
|
Vasodilator |
|
|
Use |
|
Considered as "possibly effective" for adjunctive therapy in peripheral
vascular disease and possibly senility due to cerebrovascular disease or
multi-infarct dementia; migraine prophylaxis, vertigo, tinnitus, and visual
disturbances secondary to cerebrovascular insufficiency and diabetic peripheral
polyneuropathy |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Hypersensitivity to cyclandelate or any component |
|
|
Adverse
Reactions |
|
<1%:
Central nervous system: Headache, pain, dizziness; tingling sensation in
face, fingers, or toes
Gastrointestinal: Belching, heartburn
Neuromuscular & skeletal: Weakness |
|
|
Drug
Interactions |
|
May enhance action of drugs causing
vasodilation/hypotension |
|
|
Mechanism of
Action |
|
Cyclandelate, 3,3,5-trimethylcyclohexyl mandelate is a vasodilator that
exerts a direct, papaverine-like action on smooth muscles, particularly that
found within the blood vessels. Animal data indicate that cyclandelate also has
antispasmodic properties; exhibits no adrenergic stimulation or blocking action;
action exceeds that of papaverine; mild calcium channel blocking agent, may
benefit in mild hypercalcemia; calcium channel blocking activity may explain
some of its pharmacologic effects (enhanced blood flow) and inhibition of
platelet aggregation. |
|
|
Usual Dosage |
|
Adults: Oral: Initial: 1.2-1.6 g/day in divided doses before meals and at
bedtime until response; maintenance therapy: 400-800 mg/day in 2-4 divided
doses; start with lowest dose in elderly due to hypotensive potential; decrease
dose by 200 mg decrements to achieve minimal maintenance dose; improvement can
usually be seen over weeks of therapy and prolonged use; short courses of
therapy are usually ineffective and not recommended |
|
|
Mental Health: Effects
on Mental Status |
|
May cause dizziness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None reported |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Take with meals or antacids to reduce GI distress |
|
|
Dosage Forms |
|
Capsule: 200 mg, 400 mg
Tablet: 200 mg, 400 mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|